Brian M. Jr. Gallagher Net Worth

The estimated Net Worth of Brian M. Jr. Gallagher is at least 6.29 百万$ dollars as of 2 July 2018. Brian Gallagher owns over 269,230 units of Telesis Bio Inc stock worth over 6,286,450$ and over the last 7 years Brian sold TBIO stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Brian Gallagher TBIO stock SEC Form 4 insiders trading

Brian has made over 2 trades of the Telesis Bio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Brian bought 269,230 units of TBIO stock worth 3,499,990$ on 2 July 2018.

The largest trade Brian's ever made was buying 273,333 units of Telesis Bio Inc stock on 5 July 2017 worth over 4,099,995$. On average, Brian trades about 180,854 units every 121 days since 2017. As of 2 July 2018 Brian still owns at least 3,697,912 units of Telesis Bio Inc stock.

You can see the complete history of Brian Gallagher stock trades at the bottom of the page.

What's Brian Gallagher's mailing address?

Brian's mailing address filed with the SEC is C/O S.R. ONE, LIMITED, 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN, PA, 19428.

Insiders trading at Telesis Bio Inc

Over the last 6 years, insiders at Telesis Bio Inc have traded over 269,224,467$ worth of Telesis Bio Inc stock and bought 73,047,057 units worth 2,753,701,666$ . The most active insiders traders include Sanofi、Plc Gsk、Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of 7,100,681$. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth 7,287$.

What does Telesis Bio Inc do?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Complete history of Brian Gallagher stock trades at Aileron Therapeutics Inc、Telesis Bio Inc

Telesis Bio Inc executives and stock owners

Telesis Bio Inc executives and other stock owners filed with the SEC include:

• Ronald Renaud,
  President, Chief Executive Officer, Director
• Richard Wooster,
  Chief Scientific Officer
• John Schroer,
  Chief Financial Officer, Treasurer
• Brian Fenton,
  Chief Business Officer
• Robert Plenge,
  Independent Director
• Robert Meyer,
  Independent Director
• George Demetri,
  Independent Director
• Daniel Lynch,
  Independent Chairman of the Board
• Daniella Beckman,
  Independent Director
• Owen Hughes,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Ann Barbier,
  Chief Medical Officer
• Frank DeRosa,
  Chief Technology Officer
• Paula Cloghessy,
  Chief Human Resource Officer
• Paul Burgess,
  Chief Operating Officer, Chief Legal Officer
• Michael Heartlein,
  Founder, Executive Vice President
• Paul M Meister,
  Director
• Everett Rand Sutherland,
  President
• Brian M. Jr. Gallagher,
  Director
• Ventures Fund Llc Mrl,
  10% owner
• Venture Fund Viii, L.P.Atla...,
  
• Plc Gsk,
  10% owner
• Human Genetic Therapies, In...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• James B Weissman,
  
• Michael R. Hodges,
  
• Todd Krueger,
  
• Steven J Golub,
  
• Sarah E. Hlavinka,
  
• Daniel Glenn Gibson,
  Chief Technology Officer
• Human Genetic Therapies, In...,
  
• Group Llc/Ma Baupost Group ...,
  
• Brendan Smith,
  Chief Financial Officer
• Sanofi,
  10% owner
• Ventures Gp, Llc Northpond ...,
  
• Fund Iv, Llc Broad Oak,
  10% owner
• William Snider,
  Director
• William J Kullback,
  Chief Financial Officer
• Rob Cutler,
  Chief Legal Officer
• Todd Robert Nelson,
  Chief Executive Officer
• Eric Eugene Esser,
  President & CEO
• Frank Witney,
  
• Christine A Tsingos,
  
• Annette Tumolo,
  
• Gregory J. Herrema,
  
• Jami K Nachtsheim,